

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Bloomage BioTechnology Corporation Limited **華熙生物科技有限公司**

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 00963)

ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2015

Financial Highlights

The Group's revenue amounted to approximately RMB312,002,000 for the first half of 2015, representing an increase of approximately RMB68,155,000 or approximately 27.9% as compared to the corresponding period of 2014.

The profit attributable to the equity shareholders of the Company amounted to approximately RMB99,688,000 for the first half of 2015, representing an increase of approximately RMB15,924,000 or 19.0% as compared to the corresponding period of 2014.

Excluding the effect of the non-cash equity-settled share-based payment expenses of RMB12,101,000 (the corresponding period of 2014: RMB9,920,000), the profit attributable to equity shareholders of the Company for the first half of 2015 was approximately RMB111,789,000 (the corresponding period of 2014: RMB93,684,000), representing an increase of approximately RMB18,105,000 or 19.3% as compared to the corresponding period of 2014.

The board (the "Board") of directors (the "Directors") of Bloomage BioTechnology Corporation Limited (the "Company") is pleased to announce the unaudited financial results of the Company and its subsidiaries (collectively referred to as the "Group") for the six months ended 30 June 2015 together with the comparative figures for the corresponding period in 2014.

**CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND
OTHER COMPREHENSIVE INCOME**

for the six months ended 30 June 2015-unaudited

		Six months ended 30 June	
		2015	2014
	Note	RMB'000	RMB'000
Revenue	4	312,002	243,847
Cost of sales		(83,766)	(57,294)
Gross profit		228,236	186,553
Other revenue	5	6,123	5,536
Distribution costs		(44,222)	(37,714)
Administrative expenses		(56,740)	(44,227)
Other operating expenses, net		(1,910)	(1,132)
Profit from operations		131,487	109,016
Finance costs	6(a)	(4,227)	(5,062)
Profit before taxation	6	127,260	103,954
Income tax	7	(27,573)	(20,191)
Profit for the period		99,687	83,763
Other comprehensive income for the period			
(after tax adjustments):			
Item that may be reclassified subsequently to profit or loss:			
Exchange differences on translation of financial statements of foreign operations (net of income tax)		(21)	931
Total comprehensive income for the period		99,666	84,694

**CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND
OTHER COMPREHENSIVE INCOME (continued)**
for the six months ended 30 June 2015-unaudited

		Six months ended 30 June	
		2015	2014
	Note	RMB'000	RMB'000
Profit attributable to:			
Equity shareholders of the Company		99,688	83,764
Non-controlling interests		(1)	(1)
		<hr/>	<hr/>
Profit for the period		99,687	83,763
		<hr/>	<hr/>
Total comprehensive income attributable to:			
Equity shareholders of the Company		99,668	84,692
Non-controlling interests		(2)	2
		<hr/>	<hr/>
Total comprehensive income for the period		99,666	84,694
		<hr/>	<hr/>
Earnings per share (RMB)			
Basic	8(a)	0.299	0.252
		<hr/>	<hr/>
Diluted	8(b)	0.292	0.242
		<hr/>	<hr/>

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

at 30 June 2015-unaudited

		At 30 June 2015	At 31 December 2014
	Note	RMB'000	RMB'000
Non-current assets			
Property, plant and equipment, net	9	366,753	375,622
Construction in progress		2,333	412
Intangible assets		2,061	1,160
Lease prepayments		59,815	60,470
Deferred tax assets		9,459	11,383
Total non-current assets		440,421	449,047
Current assets			
Inventories		74,324	55,082
Trade and other receivables	10	205,244	177,672
Available-for-sale financial assets		—	80,000
Restricted cash	11	230,000	15,803
Cash and cash equivalents	11	305,840	187,840
Total current assets		815,408	516,397
Current liabilities			
Secured bank loan	12	220,437	—
Trade and other payables	13	99,809	136,577
Current portion of preferred shares		11,538	10,683
Income tax payable		19,255	13,394
Total current liabilities		351,039	160,654
Net current assets		464,369	355,743
Total assets less current liabilities		904,790	804,790

CONSOLIDATED STATEMENT OF FINANCIAL POSITION (continued)

at 30 June 2015-unaudited

		At 30 June 2015	At 31 December 2014
	Note	RMB'000	RMB'000
Non-current liabilities			
Deferred income		9,653	9,337
Preferred shares	14	<u>35,635</u>	<u>42,946</u>
Total non-current liabilities		45,288	52,283
NET ASSETS		<u>859,502</u>	<u>752,507</u>
CAPITAL AND RESERVES			
Share capital		2,974	2,969
Reserves		<u>856,479</u>	<u>749,487</u>
Total equity attributable to equity shareholders of the Company		859,453	752,456
Non-controlling interests		49	51
TOTAL EQUITY		<u>859,502</u>	<u>752,507</u>

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

for the six months ended 30 June 2015-unaudited

Attributable to equity shareholders of the Company

Note	Share capital RMB'000	Share premium RMB'000	Statutory reserve RMB'000	Exchange reserve RMB'000	Other reserve RMB'000	Retained earnings RMB'000	Non-controlling interests RMB'000			Total equity RMB'000
							Total RMB'000	RMB'000	RMB'000	
Balance at 1 January 2014	2,961	92,220	44,447	(3,914)	78,677	349,895	564,286		59	564,345
Changes in equity for the six months ended 30 June 2014:										
Profit for the period	—	—	—	—	—	83,764	83,764	(1)	83,763	
Other comprehensive income	—	—	—	928	—	—	928	3	931	
Total comprehensive income for the period	—	—	—	928	—	83,764	84,692	2	84,694	
Appropriation to statutory reserves	—	—	16,745	—	—	(16,745)	—	—	—	
Dividends for the year ended 31 December 2013	15(b)	—	—	—	—	(4,960)	(4,960)	—	(4,960)	
Equity settled share-based transactions	—	—	—	—	9,920	—	9,920	—	9,920	
	—	—	16,745	—	9,920	(21,705)	4,960	—	4,960	
Balance at 30 June 2014	2,961	92,220	61,192	(2,986)	88,597	411,954	653,938	61	653,999	

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (continued)
for the six months ended 30 June 2015-unaudited

Attributable to equity shareholders of the Company

Note	Non-								Total equity RMB'000
	Share capital RMB'000	Share premium RMB'000	Statutory reserve RMB'000	Exchange reserve RMB'000	Other reserve RMB'000	Retained earnings RMB'000	Total RMB'000	controlling interests RMB'000	
Balance at 1 July 2014	2,961	92,220	61,192	(2,986)	88,597	411,954	653,938	61	653,999
Changes in equity for the six months ended 31 December 2014:									
Profit for the period	—	—	—	—	—	78,303	78,303	—	78,303
Other comprehensive income	—	—	—	(328)	—	—	(328)	(10)	(338)
Total comprehensive income for the period	—	—	—	(328)	—	78,303	77,975	(10)	77,965
Equity settled share- based transactions	—	—	—	—	16,629	—	16,629	—	16,629
Shares issued on the exercise of share options granted under share option scheme	8	5,088	—	—	(1,182)	—	3,914	—	3,914
	8	5,088	—	—	15,447	—	20,543	—	20,543
Balance at 31 December 2014	2,969	97,308	61,192	(3,314)	104,044	490,257	752,456	51	752,507

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (continued)
for the six months ended 30 June 2015-unaudited

Attributable to equity shareholders of the Company										
	Share capital	Share premium	Statutory reserve	Exchange reserve	Other reserve	Retained earnings	Total	controlling interests	Non-controlling interests	Total
Note	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
Balance at 1 January 2015	2,969	97,308	61,192	(3,314)	104,044	490,257	752,456	51	752,507	
Changes in equity for the six months ended 30 June 2015:										
Profit for the period	—	—	—	—	—	99,688	99,688	(1)	99,687	
Other comprehensive income	—	—	—	(20)	—	—	(20)	(1)	(21)	
Total comprehensive income for the period	—	—	—	(20)	—	99,688	99,668	(2)	99,666	
Appropriation to statutory reserves	—	—	20,941	—	—	(20,941)	—	—	—	—
Dividends for the year ended 31 December 2014	15(b)	—	—	—	—	(6,578)	(6,578)	—	(6,578)	
Equity settled share- based transactions	—	—	—	—	12,101	—	12,101	—	12,101	
Shares issued on the exercise of share options granted under share option scheme	5	1,801	—	—	—	—	1,806	—	1,806	
	5	1,801	20,941	—	12,101	(27,519)	7,329	—	7,329	
Balance at 30 June 2015	<u>2,974</u>	<u>99,109</u>	<u>82,133</u>	<u>(3,334)</u>	<u>116,145</u>	<u>562,426</u>	<u>859,453</u>	<u>49</u>	<u>859,502</u>	

NOTES TO THE FINANCIAL INFORMATION

1 GENERAL INFORMATION

Bloomage BioTechnology Corporation Limited (the “Company”, and together with its subsidiaries, the “Group”) is an investment holding company. Its principal subsidiaries, Bloomage Freda Biopharmaceutical Co., Ltd. (“Bloomage Biopharm”), Beijing Bloomage Hyinc Technology Company Limited and Shandong Bloomage Hyinc Biopharm Company Limited (“Shandong Bloomage Hyinc”), were established in the People’s Republic of China (the “PRC”) principally engaging in the manufacture and sale of bio-chemical products (including hyaluronic acid (“HA”) raw materials and end products).

The Company was incorporated in the Cayman Islands on 3 April 2006 as an exempted company with limited liability under the Companies Law, Cap 22 (Law 3 of 1961, as consolidated and revised) of the Cayman Islands.

2 BASIS OF PREPARATION

This interim financial report has been prepared in accordance with the applicable disclosure provisions of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Stock Exchange”), including compliance with International Accounting Standard (“IAS”) 34, *Interim financial reporting*, issued by the International Accounting Standards Board (“IASB”).

This interim financial report has been prepared in accordance with the same accounting policies adopted in the 2014 annual financial statements, except for the accounting policy changes that are expected to be reflected in the 2015 annual financial statements. Details of these changes in accounting policies are set out in Note 3.

The preparation of an interim financial report in conformity with IAS 34 requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses on a year to date basis. Actual results may differ from these estimates.

This interim financial report contains condensed consolidated financial statements and selected explanatory notes. The notes include an explanation of events and transactions that are significant to an understanding of the changes in financial position and performance of the Group since the 2014 annual financial statements. The condensed consolidated interim financial statements and notes thereon do not include all of the information required for full set of financial statements prepared in accordance with International Financial Reporting Standards (“IFRSs”) issued by the IASB.

3 CHANGES IN ACCOUNTING POLICIES

The IASB has issued the following amendments to IFRSs that are first effective for the current accounting period of the Group and the Company:

- *Annual Improvements to IFRSs 2010-2012 Cycle*
- *Annual Improvements to IFRSs 2011-2013 Cycle*

None of these developments have had a material effect on how the Group's results and financial position for the current or prior periods have been prepared or presented. The Group has not applied any new standard or interpretation that is not yet effective for the current accounting period.

4 REVENUE AND SEGMENT REPORTING

(a) *Revenue*

The principal activities of the Group are the production and sale of bio-chemical products.

Revenue represents the sales value of goods sold, net of value added tax.

	Six months ended 30 June	
	2015	2014
	<i>RMB'000</i>	<i>RMB'000</i>
HA raw materials	210,391	161,044
HA end products	100,309	82,092
Others	1,302	711
	<hr/>	<hr/>
	312,002	243,847
	<hr/>	<hr/>

(b) Segment reporting

Segment information disclosed in the interim financial report has been prepared in a manner consistent with the information used by the Group's most senior executive management for the purposes of assessing segment performance and allocating resources between segments.

The Group has presented two reportable segments for the six months ended 30 June 2015, namely domestic customers and overseas customers, for which business are derived from the production and sale of bio-chemical products.

In presenting information on the reportable segments, segment revenue is based on the geographical location of customers. The measure used for reporting segment profit is "gross profit", after deducting transportation expenses incurred. The Group's assets and liabilities are almost entirely situated in the PRC and accordingly, no information on segment assets, liabilities and capital expenditure is presented.

Information regarding the Group's reportable segments as provided to the Group's most senior executive management for the purposes of resource allocation and assessment of segment performance for the period and the reconciliation of reportable segment revenues and profit or loss are set out below.

	Domestic		Overseas			Total		
	<i>RMB'000</i>	Asia	Americas	Others	<i>RMB'000</i>			
		<i>RMB'000</i>	<i>RMB'000</i>	<i>RMB'000</i>				
Six months ended								
30 June 2015								
HA raw materials and others	145,539	28,658	22,308	15,188	211,693			
HA end products	99,722	—	—	587	100,309			
Revenue	245,261	28,658	22,308	15,775	312,002			
Segment result	189,946	17,681	5,929	10,995	224,551			
Unallocated income and expenses					(93,064)			
Profit from operations					131,487			
Finance costs					(4,227)			
Income tax					(27,573)			
Profit for the period					99,687			
Six months ended								
30 June 2014								
HA raw materials and others	111,849	18,225	19,130	12,551	161,755			
HA end products	82,092	—	—	—	82,092			
Revenue	193,941	18,225	19,130	12,551	243,847			
Segment result	154,014	8,815	13,224	8,240	184,293			
Unallocated income and expenses					(75,277)			
Profit from operations					109,016			
Finance costs					(5,062)			
Income tax					(20,191)			
Profit for the period					83,763			

5 OTHER REVENUE

	Note	Six months ended 30 June	
		2015	2014
		RMB'000	RMB'000
Government grants	(a)	723	1,120
Interest income on cash at bank		567	691
Interest income on available-for-sale financial assets		2,515	2,332
Rental income		1,249	1,301
Others		1,069	92
		<hr/>	<hr/>
		6,123	5,536
		<hr/>	<hr/>

(a) *Government grants*

The grants represented incentives and awards of RMB723,000 which were mainly in relation to the Group's expansion of business to overseas markets during the six months ended 30 June 2015 (six months ended 30 June 2014: incentives and awards of RMB1,120,000 mainly in relation to the Group's technical achievement on the research and development of HA products).

There are no unfulfilled conditions and other contingencies attached to the receipt of these government grants. There is no assurance that the Group will receive government grants in the future in respect of any of the Group's research and development and other activities.

6 PROFIT BEFORE TAXATION

Profit before taxation is arrived at after charging/(crediting):

(a) *Finance costs*

		Six months ended 30 June	
		2015	2014
		RMB'000	RMB'000
Interest on borrowings		—	657
Dividends on preferred shares (Note 14)		4,227	4,405
		<hr/>	<hr/>
		4,227	5,062
		<hr/>	<hr/>

(b) Staff costs

	Six months ended 30 June	
	2015	2014
	RMB'000	RMB'000
Salaries, wages and other benefits	42,566	31,894
Contributions to defined contribution retirement plans	3,965	2,719
Equity settled share-based transaction expenses		
– share option scheme	3,449	8,053
– group share-based payment transaction settled by the controlling shareholder	8,652	1,867
	<hr/>	<hr/>
	58,632	44,533
	<hr/>	<hr/>

(c) Other items

	Six months ended 30 June	
	2015	2014
	<i>Note</i>	RMB'000
Amortisation		
– intangible assets		84
– lease prepayments		655
Depreciation		14,646
Net foreign exchange (gain)/loss		(682)
Operating lease charges in respect of leased property, plant and equipment		3,415
Research and development costs	(i)	9,384
		<hr/>

(i) Research and development costs for the six months ended 30 June 2015 included RMB3,631,000 (six months ended 30 June 2014: RMB3,874,000) relating to staff costs and depreciation, which amounts were also included in the respective total amounts disclosed separately in Note 6(b) or above for each of these types of expenses.

7 INCOME TAX

Taxation in the consolidated statement of profit or loss and other comprehensive income represents:

	Six months ended 30 June	
	2015	2014
	<i>RMB'000</i>	<i>RMB'000</i>
Current tax - PRC income tax		
Provision for the period	25,393	19,679
Under-provision in respect of prior year	256	512
Deferred tax		
Origination and reversal of temporary differences	1,924	—
	<hr/>	<hr/>
	27,573	20,191
	<hr/>	<hr/>

(i) Provision for PRC income tax is based on a statutory rate of 25% of the assessable profit of the subsidiaries of the Group established in the PRC (the “PRC subsidiaries”).

Pursuant to the notice [Lu Ke Han Zi (2014) No.136] issued by Department of Science & Technology of Shandong Province, Finance Bureau of Shandong Province, National Taxation Bureau of Shandong Province and Local Taxation Bureau of Shandong Province on 31 October 2014, Bloomage Biopharm had satisfied certain conditions in the income tax law and was granted the qualification of advanced and new technology enterprise. Bloomage Biopharm was therefore entitled to a concession on PRC income tax of 10% for the three years from 1 January 2014 to 31 December 2016. As a result, the applicable PRC income tax rate of Bloomage Biopharm for the six months ended 30 June 2015 is 15% (six months ended 30 June 2014: 15%).

(ii) Pursuant to the PRC income tax law, non-resident enterprises without an establishment or place of business in the PRC or which have an establishment or place of business but the relevant income is not effectively connected with the establishment or place of business in the PRC, are subject to PRC income tax at the rate of 10% on various types of passive income including dividends derived from sources in the PRC (“withholding tax”).

Under the Sino-Hong Kong Double Tax Arrangement and the relevant regulations, a Hong Kong company will be liable for withholding tax at the rate of 5% for dividend income derived from the PRC if the Hong Kong Company is the “beneficial owner” and holds 25% of equity interests or more of the Chinese company directly. As approved by the National Taxation Bureau of Jinan City, Tactful World Limited (“Tactful”), a Hong Kong company as the equity holder of Bloomage Biopharm, is subject to a tax rate of 5% for the dividends received from Bloomage Biopharm.

As at 30 June 2015, temporary differences relating to the undistributed profits of Bloomage Biopharm amounted to RMB469,938,000 (31 December 2014: RMB395,163,000). Deferred tax liabilities of RMB23,497,000 (31 December 2014: RMB19,758,000) have not been recognised in respect of the tax that would be payable on the distribution of these retained profits as the Company controls the dividend policy of Bloomage Biopharm and it has been determined that it is probable that profits will not be distributed in the foreseeable future.

(iii) No provision for Hong Kong Profits Tax has been made as the Group did not have assessable profits subject to Hong Kong Profits Tax for the six months ended 30 June 2015 (six months ended 30 June 2014: Nil).

8 EARNINGS PER SHARE

(a) *Basic earnings per share*

The calculation of basic earnings per share for the six months ended 30 June 2015 is based on the profit attributable to equity shareholders of the Company of RMB99,688,000 (six months ended 30 June 2014: RMB83,764,000) and the weighted average of 333,328,000 ordinary shares (six months ended 30 June 2014: 332,000,000 ordinary shares) in issue during the interim period, calculated as follows:

(i) *Weighted average number of ordinary shares (basic)*

	Six months ended 30 June	
	2015 '000	2014 '000
Issued ordinary shares at 1 January	333,124	332,000
Effect of exercise of share options granted under share option scheme	204	—
	<hr/>	<hr/>
Weighted average number of ordinary shares (basic) at 30 June	333,328	332,000
	<hr/>	<hr/>

(b) *Diluted earnings per share*

The calculation of diluted earnings per share for the six months ended 30 June 2015 is based on the profit attributable to equity shareholders of the Company of RMB99,688,000 (six months ended 30 June 2014: RMB83,764,000) and the weighted average number of 341,064,000 ordinary shares (six months ended 30 June 2014: 346,257,000 ordinary shares), calculated as follows:

(i) *Weighted average number of ordinary shares (diluted)*

	Six months ended 30 June	
	2015 '000	2014 '000
Weighted average number of ordinary shares at 30 June	333,328	332,000
Effect of deemed issue of shares under the Company's share option scheme and for warrants granted to a director for nil consideration	7,736	14,257
	<hr/>	<hr/>
Weighted average number of ordinary shares (diluted) at 30 June	341,064	346,257
	<hr/>	<hr/>

9 PROPERTY, PLANT AND EQUIPMENT, NET

(a) *Acquisitions and disposals*

During the six months ended 30 June 2015, the Group acquired items of property, plant and equipment with a cost of RMB1,170,000 (six months ended 30 June 2014: RMB697,000). The Group disposed of property, plant and equipment with a net book value of RMB2,000 during the six months ended 30 June 2015 (six months ended 30 June 2014: RMB nil).

(b) *Transfer from construction in progress*

During the six months ended 30 June 2015, construction in progress with a cost of RMB4,609,000 (six months ended 30 June 2014: RMB1,586,000) were completed and transferred to property, plant and equipment.

(c) As at 30 June 2015, property certificates of certain properties of the Group with an aggregate net book value of RMB19,838,000 (31 December 2014: RMB181,387,000) are yet to be obtained.

(d) As at 30 June 2015, property, plant and equipment of the Group of RMB244,270,000 (31 December 2014: RMB nil) have been pledged as collateral for the issuance of letters of guarantee by a PRC bank.

10 TRADE AND OTHER RECEIVABLES

As of the end of the reporting period, the ageing analysis of trade debtors and bills receivable (which are included in trade and other receivables), based on the invoice date, is as follows:

	At 30 June 2015 <i>RMB'000</i>	At 31 December 2014 <i>RMB'000</i>
Within 3 months	134,591	137,736
3 to 6 months	30,147	10,880
6 to 9 months	5,841	8,463
9 to 12 months	4,167	1,183
Over 1 year	1,140	—
	<hr/>	<hr/>
	175,886	158,262
Less: allowance for doubtful debts	(345)	—
	<hr/>	<hr/>
Prepayments and other receivables	175,541	158,262
Other receivables due from related parties	27,369	17,087
	2,334	2,323
	<hr/>	<hr/>
	205,244	177,672
	<hr/>	<hr/>

(i) Impairment of trade receivables and bills receivable

The movement in the allowance for doubtful debts during the period/year is as follows:

	At 30 June 2015 <i>RMB'000</i>	At 31 December 2014 <i>RMB'000</i>
As at 1 January	—	—
Impairment loss recognised	345	—
As at 30 June/31 December	345	—

As at 30 June 2015, the Group's trade receivables of RMB345,000 (31 December 2014: RMB nil) were individually determined to be impaired. The individually impaired receivables related to customers that were in financial difficulties and management assessed these receivables were not expected to be recovered. Consequently, specific allowances for doubtful debts of RMB345,000 (31 December 2014: RMB nil) were recognised.

(ii) Trade receivables and bills receivable that are not impaired

The analysis of trade receivables and bills receivable, based on the current and overdue status, that are neither individually nor collectively considered to be impaired are as follows:

	As at 30 June 2015 <i>RMB'000</i>	As at 31 December 2014 <i>RMB'000</i>
Current	148,945	140,562
1 to 3 months overdue	15,794	8,054
3 to 6 months overdue	7,001	8,463
6 months to 1 year overdue	3,744	1,183
More than 1 year overdue	57	—
	175,541	158,262

The credit term for trade receivables is generally 30 to 90 days. Bills receivable are generally due within 180 days from the date of billing.

Receivables that were neither past due nor impaired relate to a wide range of customers for whom there was no recent history of default.

Receivables that were past due but not impaired relate to a number of independent customers that have a good track record with the Group. Based on past experience, the Group believes that no impairment allowance is necessary as there has not been any significant change in credit quality and these receivables were considered fully recoverable. The Group has not held any collateral over these balances.

Debtors with balances that are past due are requested to settle all outstanding balances before any further credit is granted.

11 CASH AND CASH EQUIVALENTS AND RESTRICTED CASH

	At 30 June 2015 <i>RMB'000</i>	At 31 December 2014 <i>RMB'000</i>
Cash at bank and in hand	535,840	203,643
Less: restricted cash (i)	230,000	15,803
 Cash and cash equivalents	 305,840	 187,840

(i) As at 30 June 2015, restricted cash represents time deposits placed with a PRC bank for issuance of letters of guarantee (Note 12). As at 31 December 2014, restricted cash represented time deposits placed with a bank for issuance of banker's acceptance bills.

The Group's cash at bank are mainly placed with banks in the PRC, Hong Kong, Macau, Japan and United States. RMB is not a freely convertible currency and the remittance of funds out of the PRC is subject to the exchange restriction imposed by the PRC government.

12 SECURED BANK LOAN

As at 30 June 2015, the secured bank loan represents a loan borrowed from a Macau bank for the acquisition of 37.32% issued share capital of V Plus SA, a limited liability company incorporated in Luxembourg. This loan has an expected term of 3 years, however the loan agreement contains clauses which give the lender the right to demand immediate repayment if the Group fails the bank's annual credit assessment which is determined at the bank's discretion. This bank loan is secured by letters of guarantee issued by a PRC bank. The letters of guarantee issued by the PRC bank are in turn secured by the Group's restricted cash of RMB230,000,000 (Note 11), property, plant and equipment of RMB244,270,000 (Note 9) and lease prepayments of RMB59,815,000.

13 TRADE AND OTHER PAYABLES

As of the end of the reporting period, the ageing analysis of trade creditors and bills payable (which are included in trade and other payables), based on the invoice date, is as follows:

	As at 30 June 2015 <i>RMB'000</i>	As at 31 December 2014 <i>RMB'000</i>
Within 3 month	27,445	9,979
3 to 6 months	285	19,310
Over 6 months	1,863	1,427
 Trade creditors and bills payable	 29,593	 30,716
Payables for construction of plant and purchase of equipment	24,817	59,707
Receipts in advance	12,295	25,358
Value added tax payable	8,881	7,872
Preferred share dividends payable	8,683	—
Dividends payable to the shareholders of the Company	6,578	—
Other payables due to related parties	—	570
Accrued expenses and other payables	8,962	12,354
 99,809	 136,577	

The ageing analysis of trade creditors and bills payable is as follows:

	As at 30 June 2015 <i>RMB'000</i>	As at 31 December 2014 <i>RMB'000</i>
Due within 1 month or on demand	<u>29,593</u>	<u>30,716</u>

14 PREFERRED SHARES

	Six months ended 30 June	
	2015 <i>RMB'000</i>	2014 <i>RMB'000</i>
At 1 January	53,629	54,639
Dividends during the period (Note 6(a))	4,227	4,405
Dividends of preferred shares declared	<u>(10,683)</u>	<u>(9,892)</u>
	47,173	49,152
Less: current portion of preferred shares	<u>(11,538)</u>	<u>(10,684)</u>
	35,635	38,468
As at 30 June		

15 DIVIDENDS AND CAPITAL

(a) *Dividends payable to equity shareholders attributable to the interim period*

There has been no interim dividend declared attributable to the six months ended 30 June 2015 (six months ended 30 June 2014: Nil).

(b) Dividends payable to equity shareholders attributable to the previous financial year, approved during the interim period

	Six months ended 30 June	
	2015 <i>RMB'000</i>	2014 <i>RMB'000</i>
2014 final dividends, approved during the interim period, of HK\$2.5 cents per ordinary share (2013 final dividends: HK\$1.9 cents per ordinary share)	<u>6,578</u>	<u>4,960</u>

(c) Share capital

	30 June 2015		31 December 2014	
	No. of shares '000	HK\$'000	No. of shares '000	HK\$'000
Authorised:				
Ordinary shares of				
HK\$0.01 each	<u>1,000,000</u>	<u>10,000</u>	<u>1,000,000</u>	<u>10,000</u>
 30 June 2015				
No. of shares				
	'000	RMB'000		
 Ordinary shares, issued and				
fully paid:				
At 1 January	<u>333,124</u>	<u>2,969</u>	<u>332,000</u>	<u>2,961</u>
Shares issued on exercise				
of share options granted				
under share				
option scheme	<u>518</u>	<u>5</u>	<u>1,124</u>	<u>8</u>
As at 30 June/31 December	<u><u>333,642</u></u>	<u><u>2,974</u></u>	<u><u>333,124</u></u>	<u><u>2,969</u></u>

16 CAPITAL COMMITMENTS

Capital commitments outstanding as at 30 June 2015 not provided for in the interim financial report are as follows:

	At 30 June 2015	At 31 December 2014
	<i>RMB'000</i>	<i>RMB'000</i>
Authorised and contracted for	<u>1,364</u>	<u>6,190</u>
Authorised but not contracted for	<u>—</u>	<u>—</u>
	<u><u>1,364</u></u>	<u><u>6,190</u></u>

17 MATERIAL RELATED PARTY TRANSACTIONS

(a) *Transactions with related parties*

Significant related party transactions during the six months ended 30 June 2015 are as follows:

	Six months ended 30 June	
	2015	2014
	RMB'000	RMB'000
Purchase of materials from related parties	9,179	13,136
Dividends on preferred shares paid	2,000	3,000
Lease of buildings and plant to related parties	1,249	1,301
Rental expense for lease of properties from a related party	3,389	3,672

In the opinion of the directors of the Company, the above related party transactions were conducted in the ordinary and usual course of business and on normal commercial terms.

(b) *Balances with related parties*

As at the end of the reporting period, the Group had the following balances with related parties:

	At	At
	30 June	31 December
	2015	2014
	RMB'000	RMB'000
Trade and other receivables	2,856	2,463
Trade and other payables	9,545	570
Preferred shares, including current portion	47,173	53,629
Preferred share dividends payable	8,683	—

18 EVENTS AFTER THE REPORTING PERIOD

On 26 May 2015, the Group entered into a sale and purchase agreement with three individuals (the “Vendors”), pursuant to which the Group agreed to purchase and the Vendors agreed to sell at a consideration of Euro59,000,000 (subject to adjustments) the sale shares (representing 37.32% of the issued shares of the V Plus SA), which in turn holds 89.51% of the issued share capital of Laboratoires Vivacy SAS (“Vivacy”), a French limited liability company. This transaction has been completed on 15 July 2015.

MANAGEMENT'S DISCUSSION AND ANALYSIS

OVERVIEW OF THE GROUP

Bloomage BioTechnology Corporation Limited (the “Company”, and together with its subsidiaries, the “Group”) is an investment holding company. In recent years, the Company pushed forward its strategic transformation in a steady manner, and succeeded in transforming from a raw material producer and supplier to an end product producer and service provider. Its main current business covers two areas:

The first is the development, manufacture and sale of raw materials for a diversified range of hyaluronic acid (also known as hyaluronan, sodium hyaluronate, hyaluronic acid sodium, “HA”) products and derivatives leveraging on bio-fermentation technology. HA is a naturally occurring substance that can be found in many parts of human bodies and animals, usually in the joints, vitreous humor in the eyes, skin, umbilical cord and in rooster combs. Given that HA exhibits hydrating, lubricating, viscoelastic, pseudoplastic, biodegradable and biocompatible properties, it is widely used as raw materials and excipients in pharmaceutical, cosmetic and healthcare products. The HA raw materials products of the Group include more than 70 product models under three major grades, namely pharmaceutical grade HA, cosmetic grade HA and food grade HA, which can meet product demand from different customers. The Group can also provide customized products upon request.

The second is the development, manufacture, distribution and sale of end products with HA as the main component and function feature. The main end products that the Group has successfully launched include Hyaluronan Soft Tissue Filling Gel (trade name “BioHyalux”, an injection cosmetic filler products), medical skin care products with hyaluronic acid, Medical Sodium Hyaluronate Gel for ophthalmologic use (trade name “Hymois”) and bone products for intra-articular injection (trade name “Hyprojoint”), which involve cosmetics, pharmaceuticals and other aspects of daily lives. Based on the hyaluronic acid as the core, the Group is committed to developing into the provider of the full series of products and solutions.

Adhering to scientific and technological innovation as a driving force for development and leveraging on its 20 years’ experience in research and development, the Group has constantly been looking for new breakthrough points for scientific and technological innovation, so as to seize the opportunities for future development. The Group has pushed forward its transformation and upgrade from its original products through integrating with and absorbing new technologies and products around the world, and strives to create the first “Products+ Services+ Solutions+ Platform” medical beauty ecological chain so as to deliver good performance and create more values for the society.

BUSINESS REVIEW

In the first half of 2015, the global economy presented a trend of unbalanced development, economic growth in the PRC slowed down, but high profit and high return in the beauty plastic surgery industry became a new source of wealth creation in the medical sector, and brought new market opportunities to the fast growing emerging cosmetics raw material industry. For the six months ended 30 June 2015, the Group's revenue amounted to approximately RMB312.002 million, representing an increase of approximately 27.9% as compared with approximately RMB243.847 million in the corresponding period of 2014. Its profit for the six months ended 30 June 2015 was approximately RMB99.687 million, representing an increase of approximately 19.0% from approximately RMB83.763 million in the corresponding period of 2014. Excluding the effect of the non-cash equity-settled share-based payment expenses of approximately RMB12.101 million (six months ended 30 June 2014: RMB9.920 million), the Group's profit for the six months ended 30 June 2015 was approximately RMB111.788 million (six months ended 30 June 2014: RMB93.683 million), representing an increase of approximately 19.3% as compared with the corresponding period of 2014.

HA raw material products business – sales strategy depends on category, product are optimized with continuous innovations

During the first half of 2015, the raw material business of the Group achieved remarkable results, sales increased by 30.6% year-on-year. By joining with global industry development trend, the Group decomposed and implemented the strategic objectives of the Company, and expanded the raw material market with great effort through technology innovation, service innovation, product innovation and by leveraging on such channels as exhibitions, promotions and new product seminars.

During the first half of 2015, the market prices of “food-grade” HA, in which competition was most intense, tended to be stable. Leveraging on the strategic cooperation advantages, the Group optimized its sales channels and steadily expanded its customer resources. The addition of innovative products and non-HA cosmetic raw materials provided new driving force for growth in the cosmetic grade raw material business. In the medical HA market where the Company enjoyed a technological and product edge, better sales results were achieved through channel integration and refined and professional marketing.

During the first half of 2015, the Group launched and released a number of new HA raw material products, including the first professional anti-aging, anti-haze and anti-pollution HA elastic product HyacrossTM in China based on the Company's core HA cross-linking technique, the highly harmonious HA product cationHATM designed for hair care products with scalp barrier improving function. New products were developed continuously, professional customized services were provided in response to customers' demand and all-round technical support to customers covering from product usage to assessment of effects had satisfied the multi-level product development demand of customers, and offered continuous driving momentum of growth to the raw material business of the Group.

With the completion and commencement of production of the Group's new production base, the supply capacity and product quality of the Group were further secured, and the increase in economies of scale of the new plant bases, the improvement in production efficiency upon technology upgrade and optimization of the production and allocation of products would enhance the core competitiveness of the Group and facilitate stable development of the Group.

HA end product business - comprehensively deepening strategic arrangement to advance the construction of the medical beauty ecological platform

In the first half of 2015, the Group's HA end product business continued to focus on the development of Hyaluronan Soft Tissue Filling Gel (BioHyalux); meanwhile, the Group also developed the markets for skin health and surgical products actively. The Group continued to further penetrate into the existing market for BioHyalux, revenue from end products increased by 22.2%.

In the first half of 2015, with respect to market strategies for BioHyalux, the Group cooperated with international authoritative experts to launch the unique concept of "OGEE curve" and the exclusive injection method of "BV5" lifting, which created a niche in the market and brought a new spot of growth for BioHyalux. Meanwhile, the Group further promoted the biological activated combined treatment ("BACT") and the HA medical customization centre ("Med潤 • Spa") projects, and customized exclusive treatment and care projects were launched in collaboration with a number of famous medical beauty institutions. Through various product portfolios, including BioHyalux, global avant-garde beauty equipment and unique medical skin care products, etc., customized solutions were provided to resolve personal facial problems of each customer, moving away from the situation of competition in an increasingly homogeneous market landscape with reliance on a single product, which had also developed emerging market and channel for medical skin care products of the Group.

Medical training has always been an important supporting service provided by the Group. In the first half of 2015, the Group conducted substantial specialized technical training activities through the Bloomage Institute. Trainees in the industry included doctors, consultants and institution operators. Through such professional training, the cooperative relationship among doctors, experts and BioHyalux became much closer, and not only ancillary supports for the Group's end products at the marketing level were provided, but also the Group's professional image and position in the medical beauty industry was significantly enhanced.

Research & development and quality – strengthening new product and qualification reserves, enriching product systems

In the first half of 2015, the Group continued to research and produce and reserve a number of products and obtained relevant qualifications, providing important protection for a rich product system of the Group.

The Group continuously introduced new raw material products with successful launch of HyacrossTM, the first HA elastomer in the PRC, and cationHATM, a high-affinity HA, in March 2015. On research and development of end products, a range of HA injection filler products and HA beauty shaping products are in the process of development. The technological innovation projects in Shandong, “Research and Development of HA injection fluid” and “Research and Production of HA cavity lubricant” have passed acceptance inspection.

In terms of domestic qualification, more than 10 cosmetics had completed filing procedures; the approval process for the first health food “Oral HA moisturizing capsule” (「優活膠囊」) was also completed and will obtain the health food certificate soon. Moreover, the Group had completed the development of disinfection and sanitation products and obtained the production permit for sanitation and disinfection products.

In terms of international registration, the Group has obtained the CE certificate of EU Class III medical devices for the HA injection fluid. The CEP registration document for eye drops grade hyaluronic acid (HA-E2.0, HA-E3.0) has been submitted to the European Medicines Quality Assurance Agency, and the registration of pharmaceutical grade hyaluronic acid is under the official approval process in India, South Korea and Russia.

Capital operation – integrating international advantageous resources, improving the end product industrial chain

During the first half of 2015, the Group took advantage of the world’s top-notch medical beauty product and the implementation of the “medical beauty ecological chain” strategy. The Group formed strategic cooperations with Laboratoires Vivacy SAS (“Vivacy”), an European renowned brand owner of HA injection fillers, and Medytox Inc., a Korean pharmaceutical enterprise, through acquisition of equity interest and establishment of a joint venture company which were completed on 15 July 2015 and 24 July 2015 respectively, which will drive the Group’s leaping development in China and, in turn, the international medical beauty industry.

Through equity acquisition, the Group becomes a holder of approximately 33.41% of the issued capital of Vivacy and has obtained the exclusive agency right of Vivacy products in over 20 countries and regions, including China and Australia. Vivacy was founded in 2007 and is a French company specialized in designing, developing, manufacturing and selling of anti-aging and rejuvenation products. Vivacy, being a fast growing high-end HA injection filler product provider in Europe, has avant-garde third generation HA injection filler cross-linking technique. Registration for its product in China is in the process. Its product will create synergy effect with BioHyalux to maintain the Group’s competitive advantage in the HA injection market.

Medytox owns the brand of Type A Botulinum Toxin (“Botulinum Toxin”), which is the top in terms of market share in South Korea, and is the fourth company in the world that has successfully researched and developed Botulinum Toxin and possesses outstanding global research and development capabilities. The Group and Medytox have set up a joint venture (in which each of them owns 50% equity interest) to collaborate in the development of the Botulinum Toxin market in China. Botulinum Toxin and HA are the two major core product categories in the medical beauty area. The cooperation with Medytox will be an important complement for the “contents” for the Group to establish a medical ecological chain platform, which will enable more effective utilization of the Group’s advantages of the “medical beauty ecological chain” strategy in “end-user + application + contents + platform”, establishing a solid foundation for the transformation of the Group into a medical beauty overall solution provider.

BUSINESS OUTLOOK

Looking backward, the Group has made its transformation with clear goals and firm pace from producing raw materials to producing end products, from owning a single product to owning a product portfolio and from a product supplier to a solution provider, and has explored new business fields and growth potential again and again. Looking forward, the Group will continue to establish strategic foothold in its medical beauty platform and continue to maintain the growth of its existing business in order to further increase consumers’ stickiness and improve its own competitive advantages.

In terms of HA raw materials, by leveraging on the fermentation technology platform advantages for more than 20 years and a keen and thorough understanding of cosmetics, pharmaceutical raw materials and the food industry, the Group will continue to launch the high-tech and high value-added raw material products that possess independent intellectual property rights to meet or lead the market demand. Based on the current HA series raw material products, the raw material product lines will be further enriched to meet the demand of customers for different products. Through innovatively managing the sales team, the original single region-based sales organization management will be adjusted to a compound sales organization management focusing on the product-based sales organization management, and will continuously expand sales channels and broaden product application areas. The diversified and innovative product lines, and the enhancing and transforming sales force will further ensure the stable growth and continuous enhancement of our market share.

In terms of HA end products, the Group will continue to push forward the implementation of the medical beauty ecological chain strategy and develop more business modes, through launching new products in the market and promotion and application of new technologies. Meanwhile, the Group will speed up the market layout of skin health products and surgical products, and enhance the overall BLOOMAGE brand by the combined forces of different types and varieties of products.

FINANCIAL REVIEW

Revenue

The Group's revenue for the six months ended 30 June 2015 was approximately RMB312.002 million, representing an increase of approximately 27.9% as compared to the corresponding period of 2014. The increase in revenue was mainly attributable to the increase in sales of cosmetic grade HA raw materials and HA end products. The breakdown of the Group's revenue by products was as follows:

	Six months ended 30 June			
	2015		2014	
	RMB'000	%	RMB'000	%
HA raw materials	210,391	67.4	161,044	66.0
HA end products	100,309	32.2	82,092	33.7
Others	1,302	0.4	711	0.3
Total	312,002	100.0	243,847	100.0

Cost of sales

Cost of sales of the Group for the six months ended 30 June 2015 was approximately RMB83.766 million, representing an increase of approximately 46.2% as compared to approximately RMB57.294 million for the corresponding period of 2014. The increase was mainly attributable to the increase in sales volume.

Gross profit margin

The Group's gross profit margin for the six months ended 30 June 2015 decreased to approximately 73.2% from approximately 76.5% for the corresponding period of 2014. The decrease was mainly due to the increase in the categories of HA products and change in the sales mix of HA raw materials.

Other revenue

Other revenue of the Group was approximately RMB6.123 million for the six months ended 30 June 2015, representing an increase of approximately RMB0.587 million as compared to the corresponding period of 2014. The increase in other revenue was mainly attributable to the increase of interest income from available-for-sale financial assets as compared to the six months ended 30 June 2014.

Distribution costs

The Group's distribution costs for the six months ended 30 June 2015 were approximately RMB44.222 million, representing an increase of approximately 17.3% from approximately RMB37.714 million for the corresponding period of 2014. The increase was mainly attributable to the increase in marketing costs of HA end products which is in line with the Group's strategy on promotion enhancement and business development.

Administrative expenses

The Group's administrative expenses for the six months ended 30 June 2015 were approximately RMB56.740 million, representing an increase of approximately 28.3% from approximately RMB44.227 million for the corresponding period of 2014. The increase in administrative expenses was mainly due to the increase in staff costs as a result of increase in the number of staff. Excluding the effect of the non-cash equity-settled share-based payment expenses of approximately RMB12.101 million (six months ended 30 June 2014: approximately RMB9.920 million), the Group's administrative expenses for the six months ended 30 June 2015 were approximately RMB44.639 million (six months ended 30 June 2014: approximately RMB34.307 million), representing an increase of approximately 30.1% as compared with the corresponding period of 2014.

Other operating expenses

The Group's other operating expenses for the six months ended 30 June 2015 were approximately RMB1.910 million, representing an increase of approximately 68.7% from approximately RMB1.132 million for the corresponding period of 2014.

Finance costs

The Group's finance costs for the six months ended 30 June 2015 were approximately RMB4.227 million, representing a decrease of approximately 16.5% from approximately RMB5.062 million for the corresponding period of 2014. The Group's finance costs mainly represented the dividends on the preferred shares.

Profit for the period

The Group's profit for the six months ended 30 June 2015 was approximately RMB99.687 million, representing an increase of approximately 19.0% from approximately RMB83.763 million for the corresponding period of 2014.

Liquidity and financial resources

As at 30 June 2015, the current assets of the Group were approximately RMB815.408 million (31 December 2014: approximately RMB516.397 million) and the current liabilities were approximately RMB351.039 million (31 December 2014: approximately RMB160.654 million). As at 30 June 2015, the current ratio of the Group was approximately 232.3% (31 December 2014: approximately 321.4%). The decrease in current ratio was mainly due to the increase in secured bank loan.

As at 30 June 2015, cash and cash equivalents of the Group were approximately RMB305.840 million (31 December 2014: approximately RMB187.840 million), of which approximately 19% (31 December 2014: approximately 87%) was denominated in RMB, approximately 2% (31 December 2014: approximately 6%) in Hong Kong dollars, approximately 5% (31 December 2014: approximately 7%) in United States dollars (“USD”) and approximately 2% (31 December 2014: approximately 0%) in Japanese Yen (“JPY”) and approximately 72% (31 December 2014: nil) in Euro.

The cash and cash equivalents denominated in Euro as at 30 June 2015 mainly represent the unused proceeds from the secured bank loan obtained for the acquisition of equity interest in V Plus SA. These proceeds were subsequently used upon the completion of the aforesaid acquisition.

As at 30 June 2015, the Group’s total borrowing was RMB220.437 (31 December 2014: nil).

As at 30 June 2015, total liabilities were approximately RMB396.327 million (31 December 2014: approximately RMB212.937 million). The Group’s gearing ratio (calculated by dividing total liabilities by total assets) as at 30 June 2015 was approximately 31.6% (31 December 2014: approximately 22.1%). The increase in gearing ratio as at 30 June 2015 as compared to that as at 31 December 2014 was principally attributable to the increase in secured bank loan.

Net cash generated from operating activities for the six months ended 30 June 2015 was approximately RMB72.500 million (six months ended 30 June 2014: approximately RMB62.670 million). Net cash outflow from investing activities for the six months ended 30 June 2015 was approximately RMB174.651 million (six months ended 30 June 2014: approximately RMB3.573 million). The net cash outflow from investing activities is mainly due to the increase of restricted cash of RMB214.197 million in relation to a bank loan obtained for the acquisition of equity interest in V Plus SA. Net cash inflow from financing activities for the six months ended 30 June 2015 was approximately RMB220.243 million (six months ended 30 June 2014: cash outflow from financing activities of approximately RMB44.617 million). The net cash inflow from financing activities is mainly due to the obtaining of a bank loan of RMB220.437 million for the acquisition of equity interest in V Plus SA.

The Board is of the opinion that the Group is in a strong and healthy financial position and has sufficient resources to support its operations and meet its foreseeable capital expenditures.

Foreign exchange risk and contingent liabilities

The sales of the Group were principally denominated in RMB, USD and JPY, with the majority of which denominated in RMB. The Group's secured bank loan at 30 June 2015 was denominated in Euro. Although the Group may be exposed to foreign currency exchange risks, the Board does not expect future currency fluctuations (other than the fluctuation of exchange rate of Euro) to materially impact the Group's operations. The Group has not adopted formal hedging policies and no instruments have been applied for foreign currency hedging purposes during the period under review. The Group will closely monitor the foreign exchange risk and take appropriate measures when needed to address the risk.

As at 30 June 2015, the Group had no contingent liabilities (31 December 2014: Nil).

Capital commitment

As at 30 June 2015, the capital commitment for construction of property, plant and equipment of the Group was approximately RMB1.364 million (31 December 2014: approximately RMB6.190 million).

Employee information

As at 30 June 2015, the Group had 587 employees (31 December 2014: 568 employees) the majority of whom were stationed in the PRC. Total remuneration for the six months ended 30 June 2015 amounted to approximately RMB58.632 million (six months ended 30 June 2014: approximately RMB44.533 million). The Group adopts a competitive remuneration package for its employees. Promotion and salary increment are assessed based on a performance-related basis. Share options may also be granted to staff with reference to individual's performance.

Charge on assets

As at 30 June 2015, the Group has pledged bank deposit of RMB230 million, property, plant and equipment of RMB244.270 million and lease prepayments of RMB59.815 million for issuance of letters of guarantee issued by a PRC bank that in turn secure the bank loan borrowed from a Macau bank.

Significant investment, material acquisitions and disposal of subsidiaries and associated companies

Save as disclosed below, during the six months ended 30 June 2015, there was no significant investment, material acquisition and disposal of subsidiaries and associated companies by the Group.

Acquisition of 37.32% of Issued Share Capital of V Plus SA (“V Plus”)

On 26 May 2015, the Company (as purchaser) entered into a sale and purchase agreement (the “Sale and Purchase Agreement”) with an individual (holding 858,304 shares of V Plus, representing approximately 55.02% of its entire issued share capital) (the “Major Shareholder”) and two individuals (in aggregate holding 241,000 shares of V Plus, representing approximately 15.45% of its entire issued share capital) (together with the Major Shareholders, collectively, the “Vendors”), pursuant to which the Company agreed to purchase and the Vendors agreed to sell at a consideration of EUR59,000,000 (subject to adjustment based on the Sales and Purchase Agreement) the 582,192 shares of V Plus (of which 507,232 shares to be sold by the Major Shareholder and 74,960 shares in aggregate to be sold by the two other individuals, representing 37.32% of the issued shares of V Plus, which in turn holds 15,613 shares of Laboratoires Vivacy SAS (“Vivacy”) (representing 89.51% of the issued share capital of Vivacy). Vivacy is a privately held company based in France with limited liability. For details of this acquisition, please refer to the announcement of the Company dated 26 May 2015.

Continuing connected transactions

On 18 January 2013, Beijing Bloomage Hyinc Technology Company Limited (“Beijing Bloomage Hyinc”) entered into a property leasing agreement (the “Property Leasing Agreement”) with Beijing Bloomage Central Property Management Co., Ltd (“Bloomage Property”), pursuant to which Beijing Bloomage Hyinc leases from Bloomage Property certain properties located in Beijing, the PRC as office for a term of 3 years from 1 January 2013 to 31 December 2015 at an annual rental cap of RMB6,252,261.6. As Bloomage Property is currently ultimately owned as to approximately 86.8% by Ms. Zhao Yan, the controlling shareholder of the Company, the chairman of the Company and an executive Director, Bloomage Property is a connected person of the Company under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”).

As none of the applicable percentage ratios (other than the profits ratio) for the Property Leasing Agreement in aggregate, on an annual basis, exceeds the 5% threshold under Rule 14A.76 of the Listing Rules, the Property Leasing Agreement is only subject to the reporting, annual review and announcement requirements and is exempt from the independent shareholders’ approval requirement under Chapter 14A of the Listing Rules.

Details of the Property Leasing Agreement are set out in the announcement of the Company dated 18 January 2013.

SHARE OPTION SCHEME

On 24 December 2012, 12,480,000 share options to subscribe for up to a total of 12,480,000 shares of the Company were granted to certain grantees under the share option scheme of the Company (the “Scheme”) and each share option shall entitle the holder to subscribe for one share of the Company at the exercise price of HKD4.422 per Share. 50% of the share options may be exercised within the period from 25 December 2013 to 24 December 2017 and the remaining 50% of the share options may be exercised within the period from 25 December 2014 to 24 December 2017. Details of the grant of share options are set out in the announcement of the Company dated 24 December 2012.

Furthermore, on 29 October 2013, 3,320,000 share options to subscribe for a total of 3,320,000 shares were granted to certain employees of the Group, each share option shall entitle the holder to subscribe for one share at the exercise price of HKD16.652 per share, subject to achievement of the performance target for the relevant period before the share option can be exercised. 25% of the share options may be exercised within the period from 30 October 2014 to 29 October 2018, 25% of the share options may be exercised within the period from 30 October 2015 to 29 October 2018, 25% of the share options may be exercised within the period from 30 October 2016 to 29 October 2018, and the remaining 25% share options may be exercised within the period from 30 October 2017 to 29 October 2018. Details of the grant of share options are set out in the announcement of the Company dated 29 October 2013.

Moreover, on 29 October 2013, 6,640,000 share options to subscribe for a total of 6,640,000 shares were granted to Mr. Jin Xuekun under the Scheme, each share option shall entitle Mr. Jin to subscribe for one share at the exercise price of HKD16.652 per share, subject to achievement of the performance target for the relevant period before the share option can be exercised. 25% of the share options may be exercised within the period from 23 December 2014 to 22 December 2018, 25% of the share options may be exercised within the period from 23 December 2015 to 22 December 2018, 25% of the share options may be exercised within the period from 23 December 2016 to 22 December 2018, and the remaining 25% share options may be exercised within the period from 23 December 2017 to 22 December 2018. Details of the grant of share options are set out in the announcement of the Company dated 29 October 2013.

OPTION AGREEMENT

On 22 May 2014, AIM First Investments Limited (“AFI”), Ms. Zhao Yan (“Ms. Zhao”), the chairman of the Company and an executive Director (as warrantor for AFI), Wealthy Delight Group Limited (“Wealthy Delight”) and Mr. Jin Xuekun (“Mr. Jin”), the chief executive officer of the Company and an executive Director (as warrantor for Wealthy Delight) entered into an option agreement (the “Option Agreement”), pursuant to which, (i) AFI has granted a call option to Wealthy Delight (“AFI Call Option”) exercisable during the period from 22 May 2014 to 22 May 2019 to require AFI to transfer an aggregate of 9,960,000 shares of the Company or any part thereof held by AFI (the “Option Shares”) to Wealthy Delight at HK\$5.8 per share (the “Transfer Price”); and (ii) Wealthy Delight

has granted a call option to AFI exercisable during the period commencing on the completion date of the transfer of the relevant Option Shares under the AFI Call Option and ending on 22 May 2019 to require Wealthy Delight to transfer the Option Shares or any part thereof held by Wealthy Delight to AFI at the Transfer Price on the condition that AFI Call Option has been exercised by Wealthy Delight and Mr. Jin resigns as the chief executive officer of the Company due to personal reason(s). Details of the Option Agreement are set out in the announcement of the Company dated 22 May 2014.

Subsequent events

Completion of the Acquisition of 37.32% of Issued Share Capital of V Plus

On 15 July 2015, the Company completed the acquisition of 37.32% of the issued share capital of V Plus and consideration in the sum of EUR59,000,000 was paid to the Vendors pursuant to the Sale and Purchase Agreement (the “Completion”). Upon Completion, the Company indirectly holds approximately 33.41% of the issued share capital of Vivacy. For details, please refer to the announcement of the Company dated 15 July 2015.

Formation of a Joint Venture Company

On 24 July 2015, the Company and Medytox Inc. (“Medytox”), being a limited liability company incorporated in the Republic of Korea established a joint venture company in Hong Kong (the “JV Company”). Each of the Company and Medytox has 50% shareholding in the JV Company. The JV Company will be principally engaged in the registration, promotion and sales of certain products mainly consisting of Type A Botulinum Toxin in China. For details, please refer to the announcement of the Company dated 24 July 2015.

INTERIM DIVIDEND

The Board does not recommend the declaration or payment of an interim dividend for the six months ended 30 June 2015 (six months ended 30 June 2014: Nil).

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES OF THE COMPANY

For the six months ended 30 June 2015, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the listed securities of the Company.

CORPORATE GOVERNANCE

The Company had complied with all applicable code provisions as set out in the Corporate Governance Code contained in Appendix 14 to the Listing Rules during the six months ended 30 June 2015.

AUDIT COMMITTEE

The primary duties of the audit committee of the Company (the “Audit Committee”) are to review and supervise the financial reporting process and internal control procedures of the Group. The Audit Committee comprises three independent non-executive Directors, namely Mr. Li Junhong, Ms. Zhan Lili and Mr. Hai Wen. Mr. Li Junhong is the chairman of the Audit Committee.

NOMINATION COMMITTEE

The primary duties of the Nomination Committee are to make recommendations to the Board on the appointment of Directors and management of the Board’s succession and to ensure that the candidates to be nominated as Directors are experienced, high calibre individuals. The Nomination Committee comprises one executive Director, namely Ms. Liu Aihua and two independent non-executive Directors, namely Ms. Zhan Lili and Mr. Hai Wen. Ms. Zhan Lili is the chairman of the Nomination Committee.

REMUNERATION COMMITTEE

The primary duties of the remuneration committee of the Company (the “Remuneration Committee”) are to regularly make recommendations to the Board on the Company’s policy and structure for the remuneration of all the Directors and senior management and on the establishment of a formal and transparent procedure for developing remuneration policy. The Remuneration Committee comprises Mr. Jin Xuekun, an executive Director and two independent non-executive Directors, namely Mr. Hai Wen and Mr. Li Junhong. Mr. Hai Wen is the chairman of the Remuneration Committee.

MODEL CODE SET OUT IN APPENDIX 10 TO THE LISTING RULES

The Company has adopted the Model Code set out in Appendix 10 to the Listing Rules as its own code of conduct regarding Directors’ securities transactions. The Company has also adopted the Model Code for the relevant employees.

Having made specific enquiries with all Directors, the Directors have confirmed that they have complied with the Model Code during the six months ended 30 June 2015. Moreover, no incident of non-compliance of the Model Code by the relevant employees was noted by the Company.

REVIEW OF FINANCIAL INFORMATION

The Audit Committee has reviewed the unaudited condensed consolidated financial statements of the Group for the six months ended 30 June 2015. The Audit Committee has also reviewed this result announcement, and confirms that it is complete and accurate and complies with the Listing Rules.

PUBLICATION OF THE INTERIM REPORT

The interim report will be dispatched to the shareholders and posted on the websites of the Company (www.bloomagebio-tech.com) and the Stock Exchange (www.hkexnews.hk) in due course.

By order of the Board

Bloomage BioTechnology Corporation Limited

ZHAO YAN

Chairman

Hong Kong, 26 August 2015

As at the date of this announcement, the executive Directors are Ms. Zhao Yan, Mr. Jin Xuekun, Ms. Liu Aihua and Ms. Wang Aihua; the non-executive Director is Mr. Guo Jiajun; the independent non-executive Directors are Ms. Zhan Lili, Mr. Hai Wen and Mr. Li Junhong.